



Work Group Considerations Regarding MenABCWY Vaccine and Discussion of Potential Risk Groups for MenB Vaccination

Sarah F. Schillie, MD, MPH, MBA
DBD/NCIRD

Advisory Committee on Immunization Practices

June 28, 2024

The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention

CONFIDENTIAL

GSK's MenABCWY Vaccine Clinical Development Program

■ Phase 3 studies

- V72_72: ages 10–25 years, MenACWY-naïve/MenB-naïve, N=3,638
 - 87-91% White*; 3-6% Hispanic or Latino*; 49-56% female
- MenABCWY-019: ages 15–25 years, MenACWY-primed/MenB-naïve, N=1,247
 - 75-76% White*; 29-31% Hispanic or Latino*; 52-55% female
- Comparators: MenACWY-CRM, MenB-4C 0,2 mo., MenB-4C 0,6 mo.

■ 10 Phase 1 and 2 studies

*Demographics of participants reflect countries in which studies performed


Assessment of Safety

- Phase 3 studies
 - Solicited local and systemic AEs after each dose of MenABCWY, MenACWY, and MenB

- Integrated Safety Analysis (N=7,048)
 - Unsolicited AEs within 30 days of vaccination
 - Related, leading to withdrawal, medically attended, related medically attended, SAEs, deaths

► Solicited Local and Systemic AEs within 7 Days, after Each Vaccination with MenABCWY, MenB-4C or MenACWY_{CRM}

Phase 3: V72_72



AE: adverse event; *Number of participants varies by study vaccination: 1428-1638 for MenABCWY arm, 823-835 for MenB-4C and 178 for MenACWY.
GSK, Data on File 2024N555060

4 of 32

MenABCWY Demonstrated a Well-Tolerated Safety Profile Comparable to MenB-4C

Integrated Safety Analysis (Pooled)	MenABCWY N=3,718	MenB-4C N=2,969	MenACWY _{CRM} N=361
N =7,048	n (%)	n (%)	n (%)
Unsolicited AEs (within 30 days of any vaccination)	1,072 (29%)	736 (25%)	47 (13%)
Related*	256 (7%)	155 (6%)	10 (3%)
AEs leading to withdrawal	8 (0.2%)	4 (0.1%)	0
Medically attended AEs†	416 (12%)	302 (11%)	8 (4%)
Related medically attended AEs†	22 (0.6%)	15 (0.5%)	0
SAEs (entire study period)	70 (1.9%)	58 (2%)	5 (1.4%)
Related*	3 (0.1%)	2‡ (0.1%)	0
Deaths (all unrelated)	1§	2¶	1§

*Assigned as related by investigator; †Medically attended flags for AEs are not available in studies V102P1, V102_02, V102_02E1 and V102_03. Participants from these studies are not included. Therefore, the denominator is different for the 3 groups (MenABCWY N=3488, MenB N=2861, MenACWY N=213); ‡2 SAEs occurred in the MenB-4C arms of the studies included in the pooled safety analysis: 1 SAE followed a MenB-4C and 1 followed a MenACWY-CRM vaccination; §Suicide; ¶Deaths by poisoning and drug overdose; AE: adverse event; SAE: serious adverse event
GSK, Data on File 2024N555058.

Solicited and Unsolicited AE Following Vaccination

- Solicited AE:
 - Local AE: $\text{MenABCWY} \approx \text{MenB}$ and $\text{MenABCWY} > \text{MenACWY}$
 - Systemic AE: $\text{MenABCWY} \approx \text{MenB} \approx \text{MenACWY}$

- Unsolicited AE:
 - MenABCWY slightly greater than MenB and greater than MenACWY
 - Except for AE leading to withdrawal during the entire study period:
 $\text{MenABCWY} \approx \text{MenB} < \text{MenACWY}$

SAEs and Deaths

- SAE during entire study period: MenABCWY≈MenB>MenACWY (all ≤2%)
 - Related SAE during entire study period: MenABCWY≈MenB>MenACWY (all ≤0.1%)
 - 4 of 5 resolved or partially resolved (seizure*, connective tissue disorder*, neuromyelitis optica*, pyrexia/nausea/vomiting/headache¥)
 - 1 ongoing (ulcerative colitis† with positive family history for Crohn's disease)
- Deaths (all unrelated)
 - MenABCWY recipients (1): suicide
 - MenB recipients (2): drug overdose, poisoning
 - MenACWY recipients (1): suicide

*MenABCWY vaccine recipient, ¥MenACWY recipient, †MenB recipient
SAE, serious adverse event

Immunogenicity Assessment



- Serogroup A, C, W, Y
 - Seroresponse: 4-fold rise in hSBA titers

- Serogroup B
 - Seroresponse: 4-fold rise in hSBA titers
 - enc-hSBA assay: Assessment of protection against diverse disease-causing serogroup B strains
 - 110 randomly selected strains that represent 95% of U.S. “disease-causing” strains

MenABCWY Non-Inferior to MenACWY_{CRM} in MenACWY-Naïve and MenACWY-Primed Participants

V72_72:
MenACWY-Naïve

% with 4-fold Rise
in hSBA Titers*†
(95% CI)





MenABCWY
(2 doses)

MenABCWY
(1st dose)

MenACWY
(1 dose)

MenABCWY-019:
MenACWY-Primed**

% with 4-fold Rise
in hSBA Titers*†
(95% CI)




*At 1 month after 1 or 2 doses of MenABCWY or after single MenACWY vaccination; †Defined as a post-vaccination titer ≥4-fold the LOD or ≥LLOQ, whichever is greater if pre-vaccination titer <LOD, a post-vaccination titer ≥4-fold the LLOQ if pre-vaccination titer ≥LOD and <LLOQ, and a post-vaccination titer ≥4-fold the pre-vaccination titer if pre-vaccination titer ≥LLOQ. LOD: 4 for MenA, MenC, MenW, and MenY. LLOQ = 12 for MenA; 8 for MenC; 8 for MenW; 10 for MenY, except for the post-hoc analysis for which LLOQs were 8 for MenA and 11 for MenC; ‡Licensure criteria agreed with CBER; *full set analysis; **Primed participants had received a dose of MenACWY vaccine at least 4 years prior. CI – confidence interval, hSBA – human serum bactericidal assay, LOD – limit of detection; LLOQ – lower limit of quantitation
1. Clinicaltrials.gov identifier [NCT04502693](https://clinicaltrials.gov/ct2/show/study/NCT04502693), accessed May 31st, 2024; 2. Clinicaltrials.gov identifier [NCT04707391](https://clinicaltrials.gov/ct2/show/study/NCT04707391), accessed May 31st, 2024; 3. GSK, Data on File 2024N555056.

Presentation by GSK at ACIP, June 2024

MenABCWY Non-Inferior to MenACWY_{CRM} in MenACWY-Naïve and MenACWY-Primed Participants

V72_72: MenACWY-Naïve

% with 4-fold Rise
in hSBA Titers*†
(95% CI)




■ 2 doses MenABCWY non-inferior to 1 dose MenACWY

- MenACWY-naïve and primed recipients

MenABCWY-019: MenACWY-Primed**


% with 4-fold Rise
in hSBA Titers*†
(95% CI)



*At 1 month after 1 or 2 doses of MenABCWY or after single MenACWY vaccination; †Defined as a post-vaccination titer ≥4-fold the LOD or ≥LLOQ, whichever is greater if pre-vaccination titer <LOD, a post-vaccination titer ≥4-fold the LLOQ if pre-vaccination titer ≥LOD and <LLOQ, and a post-vaccination titer ≥4-fold the pre-vaccination titer if pre-vaccination titer ≥LLOQ. LOD: 4 for MenA, MenC, MenW, and MenY. LLOQ = 12 for MenA; 8 for MenC; 8 for MenW; 10 for MenY, except for the post-hoc analysis for which LLOQs were 8 for MenA and 11 for MenC; ‡Licensure criteria agreed with CBER; *full set analysis; **Primed participants had received a dose of MenACWY vaccine at least 4 years prior. CI – confidence interval, hSBA – human serum bactericidal assay, LOD – limit of detection; LLOQ – lower limit of quantitation
1. Clinicaltrials.gov identifier [NCT04502693](https://clinicaltrials.gov/ct2/show/study/NCT04502693), accessed May 31st, 2024; 2. Clinicaltrials.gov identifier [NCT04707391](https://clinicaltrials.gov/ct2/show/study/NCT04707391), accessed May 31st, 2024; 3. GSK, Data on File 2024N555056.

MenABCWY Non-Inferior to MenACWY_{CRM} in MenACWY-Naïve and MenACWY-Primed Participants



- 1 dose MenABCWY non-inferior to 1 dose MenACWY in MenACWY-primed recipients
 - Naïve recipients: ad hoc analysis; confidence intervals overlap for all 4 serogroups
 - Responses greater for MenABCWY recipients compared to MenACWY recipients
 - Except for serogroup A (rare in U.S.)



whichever is greater if pre-vaccination titer < LOD, a post-vaccination titer ≥ 4-fold the LLOQ if pre-vaccination titer ≥ LOD and < LLOQ, and ≥ 8 for MenC; 8 for MenW; 10 for MenY, except for the post-hoc analysis for which LLOQs were 8 for MenA and 11 for MenC; confidence interval, hSBA - human serum bactericidal assay, LOD - limit of detection; LLOQ - lower limit of quantitation
 data on File 2024N555056.

Presentation by GSK at ACIP, June 2024

hSBA: MenABCWY Immune Response Against Serogroup B Reference Strains



- Secondary endpoint not met because success criterion not met for all 4 strains
- MenABCWY elicited comparable immune responses for 3 reference strains vs MenB-4C 0,2 and 2 reference strains vs MenB-4C 0,6m.


*At 1 month after 2nd MenABCWY or 2nd MenB-4C vaccination, relative to baseline. 4-fold rise in hSBA titer for each strain was defined as a post-vaccination titer ≥ 4 -fold the LOD or \geq LLOQ, whichever is greater if pre-vaccination titer <LOD, a post-vaccination titer ≥ 4 -fold the LLOQ if pre-vaccination titer \geq LOD and <LLOQ, and a post-vaccination titer ≥ 4 -fold the pre-vaccination titer if pre-vaccination titer \geq LLOQ. LOD – limit of detection; LLOQ – lower limit of quantitation; fHbp: 3; NadA: 6; NHBA: 4; PorA P1.4: 4. LLOQ: fHbp: 5; NadA: 15; NHBA: 4; PorA P1.4: 6. fHbp, factor H binding protein; hSBA, human serum bactericidal assay; LL, lower limit; LOD – limit of detection; LLOQ – lower limit of quantitation; NadA, Neisseria adhesin A; NHBA, Neisserial heparin-binding antigen; PorA P1.4, porin A

Clinicaltrials.gov identifier [NCT04502693](https://clinicaltrials.gov/ct2/show/study/NCT04502693), accessed May 31st, 2024

► hSBA: MenABCWY Immune Response Against Serogroup B Reference Strains

MenABCWY 0,6m vs MenB-4C 0,2 m

Group difference: (95%CI)	5.02 (0.6 to 9.4)	-3.68 (-6.2 to -1.3)	3.31 (-1.8 to 8.4)	-11.06 (-16.3 to -5.7)
---------------------------	-------------------	----------------------	--------------------	------------------------




- MenABCWY vs. MenB 0,2:
 - Success criterion met for 3 of 4 strains (fHbp, NadA, NHBA)

- Secondary endpoint not met because success criterion not met for all 4 strains
- MenABCWY elicited comparable immune responses for 3 reference strains vs MenB-4C 0,2 and 2 reference strains vs MenB-4C 0,6m.

*At 1 month after 2nd MenABCWY or 2nd MenB-4C vaccination, relative to baseline. 4-fold rise in hSBA titer for each strain was defined as a post-vaccination titer ≥ 4 -fold the LOD or \geq LLOQ, whichever is greater if pre-vaccination titer <LOD, a post-vaccination titer ≥ 4 -fold the LLOQ if pre-vaccination titer \geq LOD and <LLOQ, and a post-vaccination titer ≥ 4 -fold the pre-vaccination titer if pre-vaccination titer \geq LLOQ. LOD – limit of detection; LLOQ – lower limit of quantitation; LOD: fHbp: 3; NadA: 6; NHBA: 4; PorA P1.4: 4. LLOQ: fHbp: 5; NadA: 15; NHBA: 4; PorA P1.4: 6. fHbp, factor H binding protein; hSBA, human serum bactericidal assay; LL, lower limit; LOD – limit of detection; LLOQ – lower limit of quantitation; NadA, *Neisseria* adhesin A; NHBA, Neisserial heparin-binding antigen; Por A P1.4, porin A
Clinicaltrials.gov identifier [NCT04502693](https://clinicaltrials.gov/ct2/show/study/NCT04502693), accessed May 31st, 2024

► hSBA: MenABCWY Immune Response Against Serogroup B Reference Strains

- MenABCWY vs. MenB 0,6:
 - Success criterion met for 2 of 4 strains (fHbp, NadA)




- Secondary endpoint not met because success criterion not met for all 4 strains
- MenABCWY elicited comparable immune responses for 3 reference strains vs MenB-4C 0,2 and 2 reference strains vs MenB-4C 0,6m.

*At 1 month after 2nd MenABCWY or 2nd MenB-4C vaccination, relative to baseline. 4-fold rise in hSBA titer for each strain was defined as a post-vaccination titer ≥ 4 -fold the LOD or \geq LLOQ, whichever is greater if pre-vaccination titer $<$ LOD, a post-vaccination titer ≥ 4 -fold the LLOQ if pre-vaccination titer \geq LOD and $<$ LLOQ, and a post-vaccination titer ≥ 4 -fold the pre-vaccination titer if pre-vaccination titer \geq LLOQ. LOD – limit of detection; LLOQ – lower limit of quantitation; LOD: fHbp: 3; NadA: 6; NHBA: 4; PorA P1.4: 4. LLOQ: fHbp: 5; NadA: 15; NHBA: 4; PorA P1.4: 6. fHbp, factor H binding protein; hSBA, human serum bactericidal assay; LL, lower limit; LOD – limit of detection; LLOQ – lower limit of quantitation; NadA, *Neisseria* adhesin A; NHBA, *Neisseria* heparin-binding antigen; PorA P1.4, porin A
Clinicaltrials.gov identifier [NCT04502693](https://clinicaltrials.gov/ct2/show/study/NCT04502693), accessed May 31st, 2024

► enc-hSBA: Immune Response against Diverse Serogroup B Strains after 2 doses of MenABCWY or MenB-4C


Test-Based IVE

→ *Informs breadth of MenB vaccine strain coverage at a population level*



Responder-Based IVE


→ *% participants achieving broad protection against serogroup B strains*



MenABCWY achieved breadth of bactericidal effect against a diverse and broad panel of serogroup B strains, similar to MenB-4C 2-dose administered 2 or 6 months apart

The 3 MenB-4C schedules were hierarchically tested for IVE in the order: MenB-4C 0-2-6m → MenB-4C 0-6m → MenB-4C 0-2m. The 0-2m schedule was the last schedule to meet the predefined success criterion (LL of 95% CI > 65%) and was hence chosen as the comparator for the MenABCWY 0-6m schedule for all subsequent statistical analyses. LL, lower limit; IVE: immunological vaccine effectiveness
Clinicaltrials.gov identifier [NCT04502693](https://clinicaltrials.gov/ct2/show/study/NCT04502693), accessed May 31st, 2024

► enc-hSBA: Noninferiority of Immune Response against Diverse Serogroup B Strains in MenABCWY vs MenB-4C



*The 3 MenB-4C schedules were hierarchically tested for IVE in the order: MenB-4C 0-2-6m → MenB-4C 0-6m → MenB-4C 0-2m. The 0-2m schedule was the last schedule to meet the predefined success criterion (LL of 97.5% CI > 65%) and was hence chosen as the comparator for the MenABCWY 0-6m schedule for all subsequent statistical analyses. LL, lower limit
Clinicaltrials.gov identifier [NCT04502693](https://clinicaltrials.gov/ct2/show/study/NCT04502693), accessed May 31st, 2024

Presentation by GSK at ACIP, June 2024

Immunogenicity for Serogroup B: enc-hSBA


- Success criterion met
 - Compared to MenB 0,2 and MenB 0,6
 - Test-based and responder-based IVE
- Response slightly higher for MenB vs. MenABCWY
 - Slightly higher for MenB 0,6 vs. MenB 0,2

Persistence After 24 months and Booster Response of MenABCWY Demonstrated Against Serogroup B Reference Strains

Study 15E1

MenABCWY 0,6m (n=74)

MenB-4C 0,2m (n=126)



*For follow-on group: blood draws were done at baseline and 5 days after booster dose. For the Matched Naive group: blood draws were baseline (prevaccination), 1 month after 1st dose and 5 days after 2nd dose. fHbp, factor H binding protein; hSBA, serum bactericidal assay using human complement; LLOQ, lower limit of quantitation; NadA, Neisseria adhesin A; NHBA, Neisseria heparin binding antigen; PorA, porin A. The LLOQs were 8.0 (fHbp), 8.6 (NadA), 8.9 (NHBA), 8.2 (PorA). Vesikari T et al. *Hum Vaccin Immunother.* 2021;17(11):4689-4700

Presentation by GSK at ACIP, June 20

Persistence and Booster Response

■ MenB

- After 24 months, titers waned substantially for B strains fHbp, NHBA, and PorA
- Robust booster response elicited
- Confidence intervals overlapped (MenABCWY and MenB 0,2)

■ MenACWY

- After 24 months, titers waned substantially for serogroup A; variable waning noted for other serogroups
- Robust booster response elicited

Summary

- Favorable safety profile
 - Similar to MenB (more adverse events for MenABCWY than MenACWY)
- Immunogenicity against serogroups A, C, W, Y
 - MenABCWY non-inferior to MenACWY in most study groups
 - Comparison of 1 dose MenABCWY vs. 1 dose MenACWY in naïve recipients not powered for noninferiority; results favorable for all serogroups except A
- Immunogenicity against serogroup B strains
 - MenABCWY non-inferior to MenB based on IVE
 - MenABCWY non-inferior to MenB 0,2 for 3 strains and MenB 0,6 for 2 strains
- Persistence and booster response
 - After 24 months, titers waned substantially for serogroup A and for 3 B strains
 - Robust booster response elicited

Additional Work Group Reflections

- Concern about drop in protection at 2 years for serogroup B strains
- PorA indicator strain is important because it is not really PorA alone but rather represents the full outer membrane vesicle component of the vaccine
 - Response to this indicator strain has bearing on cross-protection

Potential Risk Groups for MenB Vaccination

Schedule Options Under Consideration

Option	ACWY Dose#1	ACWY Dose#2	B Dose#1	B Dose#2
Current recomm.	11–12 yrs	16 yrs	16 yrs – 23 years (preferred 16–18 yrs) SCDM	
1	11–12 yrs	16 yrs	16 yrs	17–18 yrs
2	11–12 yrs	16 yrs	16 yrs risk-based	17–18 yrs risk-based
3	No dose	16 yrs	16 yrs risk-based	17–18 yrs risk-based
4	15 yrs	17–18 yrs	17–18 yrs	17–18 yrs
5 (ACIP)	No dose	16 yrs	16 yrs	17–18 yrs

Proposed recommendations are for routine vaccination unless specified as “risk-based”; option numbers do not represent ordering of preference

Identify Risk Groups for MenB Vaccination

- Based on congregate living settings among adolescents
 - Recommendations will not address military/non-civilian populations as per the ACIP charter

Potential Risk Groups for MenB Vaccination

- College students (4-year students, 1st year students, on-campus residence)
- Boarding schools
- Congregate foster care
- Correctional or detention facilities
- Homeless or emergency shelters
- Institutions for persons with developmental disabilities
- Psychiatric institutions
- Residential treatment centers
- Religious academies
- Wilderness programs, summer camps
- Seasonal worker housing (including agricultural workers)
- College preparatory experiences
- Hotels, motels, and hostels

Duration of Congregate Living Risk Should Exceed Time to Complete Vaccine Series

- College students (4-year students, 1st year students, on-campus residence)
- Boarding schools
- Congregate foster care
- Correctional or ~~detention~~ facilities
- ~~Homeless or emergency shelters~~
- Institutions for persons with developmental disabilities
- Psychiatric institutions
- ~~Residential treatment centers~~
- Religious academies
- ~~Wilderness programs, summer camps~~
- ~~Seasonal worker housing (including agricultural workers)~~
- ~~College preparatory experiences~~
- ~~Hotels, motels, and hostels~~

Factors Associated with Increased Serogroup B Risk among College Students

- 4-year college students had a **5.2-fold** (95% CI: 3.6-7.7) higher risk of serogroup B disease than non-undergraduates aged 18-24 years
 - Risk among 2-year college students was comparable to non-undergraduates (RR 1.0, 95% CI 0.4-2.1)
- First-year students were at **3.8-fold** (95% CI: 2.4-6.0) higher risk of serogroup B disease than non-first-year students
- On-campus residents were at **2.9-fold** (95% CI: 1.8-4.6) higher risk of serogroup B disease than off-campus residents
- Students participating in Greek life were at **9.8-fold** (95% CI: 4.6-21.2) higher risk of serogroup B disease than other students during outbreaks

College Students

- Work Group prefers to include all college students
 - Simplifies recommendations
 - College plans may change
 - Equity considerations

Number of Students at U.S. Colleges and Boarding Schools

- Number of 18 year-olds (in 2020): 4,159,857
- Recent high school completers* in 2022: 2,987,000
 - Percentage of recent high school completers enrolled in college: 62.0%
 - 2-year college: 16.9%
 - 4-year college or university: 45.1%
- >35,000 students enrolled in U.S. boarding schools
 - Older students, many may be likely to attend college

*Includes those who completed a GED or other high school equivalency credential
GED, General Educational Development

[Bridged-Race Population Estimates 1990-2020 Results Form \(cdc.gov\)](#)

[Number of recent high school completers and percent enrolled in college, by sex and level of institution: 1960 through 2022](#)

[Why Kids Go to Boarding School \(usnews.com\)](#)

Public Foster Care System

- Continuum of foster care
 - Includes children through 18–21 years (varies by state)
 - Foster family home, group home, residential program
 - May or may not include congregate care settings
- Public foster care system served 570,000 children in 2022
 - 369,000 children in care on September 30, 2022
- Federal law requires children to be placed in least restrictive, most family-like setting
 - Number placed in congregate care decreasing
 - Those in congregate foster care typically spend ~8 months

Inclusive Language

- Work Group prefers to add inclusive language to risk-groups
 - Such that any adolescent who desires protection may receive MenB vaccine
 - Includes those who are unsure of their future plans, which may inform congregate living risk

Proposed Language

- Risk group includes adolescents planning to attend college and adolescents in a congregate living setting (e.g., congregate foster care, boarding school, correctional facility, etc.) who are anticipated to remain in this setting long enough to complete the MenB vaccine series
- Any adolescent who desires protection may receive MenB vaccine, even if they are unsure of their future plans which may inform congregate living risk